Published in Neurology on September 26, 2000
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
Epidemiology of Parkinson's disease. J Neurol (2008) 1.38
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol (2009) 1.05
Progression of parkinsonism in multiple system atrophy. J Neurol (2005) 1.05
How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm (Vienna) (2005) 1.01
An update on the cerebellar subtype of multiple system atrophy. Cerebellum Ataxias (2014) 0.91
Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. Eur J Nucl Med Mol Imaging (2012) 0.88
Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry (2014) 0.87
Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy. J Mov Disord (2009) 0.76
Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. Parkinsons Dis (2016) 0.75
Robust Bayesian hierarchical model using normal/independent distributions. Biom J (2015) 0.75
The Natural Progression of Parkinson's Disease in a Small Cohort with 15 Drug-naïve Patients. Chin Med J (Engl) (2015) 0.75
Serum 25-hydroxyvitamin D predicts severity in Parkinson's disease patients. Neurol Sci (2013) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The FAB: a Frontal Assessment Battery at bedside. Neurology (2000) 8.93
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ (2000) 7.36
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) BMJ (1996) 2.42
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
Apathy is not depression. J Neuropsychiatry Clin Neurosci (1998) 2.24
Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation (1997) 2.18
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Cognitive planning deficit in patients with cerebellar atrophy. Neurology (1992) 2.03
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (1971) 1.89
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease): three cases without evidence of "flexion myelopathy". Acta Neurol Scand (2001) 1.74
Closed suction surgical wound drainage after orthopaedic surgery. Cochrane Database Syst Rev (2007) 1.73
Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res (1998) 1.71
Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol (1999) 1.71
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry (2000) 1.70
The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol (1991) 1.69
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry (1996) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol (2012) 1.57
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
The role of ferritin and hemosiderin in the MR appearance of cerebral hemorrhage: a histopathologic biochemical study in rats. AJNR Am J Neuroradiol (1990) 1.53
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology (2001) 1.51
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol (2002) 1.51
Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand (2003) 1.50
No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol (2000) 1.49
Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology (2007) 1.48
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation (1999) 1.46
Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology (2002) 1.46
Vascular malformations of the central nervous system: a morphological overview. Neurosurg Rev (1986) 1.45
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (1998) 1.45
Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology (2008) 1.45
Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control? Eur J Neurol (2003) 1.45
Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther (2008) 1.45
Ataxia without telangiectasia masquerading as benign hereditary chorea. Mov Disord (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 1.44
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology (1999) 1.42
Caregiving in progressive supranuclear palsy. Neurology (1998) 1.42
Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience (2002) 1.42
Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1.41
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (1995) 1.40
[Neuroaxonal dystrophies]. Verh Dtsch Ges Pathol (1968) 1.40
Transient restless legs syndrome after spinal anesthesia: a prospective study. Neurology (2002) 1.39
Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses. Eur J Neurol (2003) 1.39
[Vascular parkinsonian syndrome]. Nervenarzt (2006) 1.39
[Spinal fibrocartilaginous embolism]. Nervenarzt (2005) 1.39
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Cortical and brain stem hyperexcitability in striatonigral degeneration. Mov Disord (1998) 1.38
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol (2011) 1.37